Scalable VHH and Peptide Secretion Platform Using C. glutamicum, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into the methods available for protein and peptide production and how to choose the best method to use. The featured speakers will discuss how technical advancements in microbial platforms can contribute to R&D and manufacturing of biologics. Attendees will learn about an innovative secretion platform for heavy-chain-only antibodies (VHH) and peptides that is highly productive, scalable and sustainable.
TORONTO, Aug. 27, 2025 /PRNewswire/ -- Drug developers seeking to determine the appropriate manufacturing method for a given protein and/or peptide should consider the general advantages and disadvantages of each available platform. Additional factors such as molecular structure, total yield, development phase and future volumes and scale must also be considered.
Below is a brief overview of three common approaches, each with its own benefits and limitations.
I. E. coli Expression
E. coli is a widely used, cost-effective platform for protein production, but its downstream processing and endotoxin-related challenges may limit its suitability for certain molecules.
II. Solid-Phase Synthesis
Solid-phase synthesis enables fast and flexible peptide manufacturing at a small scale; however, its limited scalability and reagent intensity make it less viable for large-scale production.
III. VHH and Peptide Secretion Platform
A microbial secretion system based on C. glutamicum provides a scalable and sustainable alternative for producing a diverse range of heavy-chain-only antibodies (VHH) and peptides with high purity and minimal downstream complexity.
While there is a wide variety of methods for protein and peptide manufacturing, each possesses unique advantages and challenges.
Register for this webinar to learn how an alternative VHH and peptide secretion platform can complement other manufacturing methods and support the R&D and production of VHHs, peptides and related biologics.
Join experts from Ajinomoto Co., Inc., Teruhisa Mannen, PhD, Executive Specialist and General Manager of Biomanufacturing Group, Research Institute for Bioscience Products & Fine Chemicals; and Yohei Yamada, Associate General Manager, Business Development Group, Bio-Pharma Services Dept., for the live webinar on Tuesday, September 16, 2025, at 10am EDT (4pm CEST).
For more information, or to register for this event, visit Scalable VHH and Peptide Secretion Platform Using C. glutamicum.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/scalable-vhh-and-peptide-secretion-platform-using-c-glutamicum-upcoming-webinar-hosted-by-xtalks-302539330.html
SOURCE Xtalks